ClinicalTrials.gg
RecruitingNCT06553976SP-CERNUpdated Mar 18, 2026

Spastic Paraplegia - Centers of Excellence Research Network

An observational study in Hereditary Spastic Paraplegia, Primary Lateral Sclerosis and SPG4, sponsored by Boston Children's Hospital. Recruiting at 11 sites in United States. Per ClinicalTrials.gov, last updated 2026-03-18.

Sponsored by Boston Children's Hospital · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as recruiting.
  • Started Jun 2024; still recruiting 2 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Spastic Paraplegia, Hereditary with a site in United States — 7 open to participants now, 10 under way, none of them phase 3. Spastic Paraplegia, Hereditary · United States.

Planned enrollment
7th of 11
100 · median 200
Started
2024
with 1 other
Observational
11 of 18
4 open now
Registered
13th of 18
by date
Lead sponsor
3 of 18
Boston Children's Hospital

Among the 18 studies in Spastic Paraplegia, Hereditary with a site in United States, this one is the 7th largest by planned enrollment of the 11 observational ones that give a count, is one of 2 that started in 2024, is one of 11 observational ones, and was the 13th registered.

Spastic Paraplegia, Hereditary

51 studies on the registry are indexed under Spastic Paraplegia, Hereditary; 20 are open to participants now.

Browse Spastic Paraplegia, Hereditary studies →

Open to participants now

7 of the 18 studies in Spastic Paraplegia, Hereditary with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 17 Spastic Paraplegia, Hereditary studies recruiting now, 10 (59%) set no upper age limit and 7 (41%) stop at 75 or younger; 13 take children under 18; 3 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Spastic Paraplegia, Hereditary with a site in United States, or all of them as a file.
02

Study summary

The Spastic Paraplegia - Centers of Excellence Research Network (SP-CERN) is a collaborative research consortium dedicated to advancing the understanding, diagnosis, and treatment of hereditary spastic paraplegia (HSP) and primary lateral sclerosis (PLS). Aims of the consortium are to a) perform natural history studies of HSP subtypes, b) discover and validate biomarkers and clinician- and patient-reported outcome measures, c) uncover HSP's molecular pathophysiology and develop rational therapeutic targets, and d) perform sufficiently powered clinical trials. The current pilot study is aimed at enrolling 100 individuals with hereditary spastic paraplegia type 4 (SPG4) or hereditary spastic paraplegia type 5A (SPG5A).

Read the detailed description

The hereditary spastic paraplegias (HSPs) include over 80 rare neurogenetic disorders, collectively representing the most prevalent cause of inherited spasticity and related disabilities globally. In all forms of HSP, there is a progressive deterioration of the long axonal tracts, resulting in substantial motor dysfunction and various other symptoms. Primary lateral sclerosis (PLS) is a related, degenerative neurological disorder characterized by the progressive deterioration of upper motor neurons. Both conditions result in muscle weakness and spasticity, with significant morbidity and impact on quality of life.

The Spastic Paraplegia - Centers of Excellence Research Network (SP-CERN) is a collaborative research consortium dedicated to advancing the understanding, diagnosis, and treatment of hereditary spastic paraplegia (HSP) and primary lateral sclerosis (PLS). SP-CERN provides a registry and natural history study across the whole age span, a biobank, and a genome archive. This will set the stage for a multitude of opportunities for improved diagnosis and trial readiness. A second objective is to harmonize this effort with similar consortia, especially in Europe, in addition to Asia, South America, and Africa, to help accelerate basic and clinical research on HSP and PLS on a global level. In summary, SP-CERN will support critical research infrastructure for collaborative high-quality research on HSP and PLS in North America and beyond.

General aims include:

A. Establish a shared clinical database, a repository of biospecimen samples, and a central database for the storage of all genetic data in SP-CERN.

B. Synchronize and harmonize collaborations between institutions, clinical sites, and international collaborators through the development of a central research protocol in order to standardize outcome measures and maximize the quality of research and data to ensure clinical trial readiness by regulatory standards.

C. Build comprehensive programs for advancements in diagnosis, provide more opportunities for innovative treatments, and increase access to high-quality healthcare for HSP and PLS patients.

Specific aims for this first pilot study are:

1a. Enrollment of 100 individuals with genetically-confirmed hereditary spastic paraplegia type 4 (SPG4) or hereditary spastic paraplegia type 5A (SPG5A) in the shared clinical database.

1b. Biobanking of blood samples from 100 individuals with SPG4 or SPG5A in a shared biobank.

03

Conditions studied

  • Hereditary Spastic Paraplegia
  • Primary Lateral Sclerosis
  • SPG4
  • SPG5A
  • Spastic Paraplegia 4
  • Spastic Paraplegia 5A
  • Early Onset Hereditary Spastic Paraplegia
  • Neuromuscular Diseases
  • Spastic Paraplegia, Hereditary
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

This study will enroll individuals with a known clinical and molecular diagnosis of spastic hereditary paraplegia type 4 (SPG4, SPAST) or Hereditary Spastic Paraplegia type 5A (SPG5A, CYP7B1), and/or their family members of interest (if applicable). We plan to enroll at least 100 individuals under a shared regulatory, data, and sample infrastructure over a 2-year time period.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female patients of all ages with a clinical and molecular diagnosis of hereditary spastic paraplegia type 4 (SPG4, SPAST) or hereditary spastic paraplegia type 5A (SPG5A, CYP7B1).

Exclusion criteria

Exclusion Criteria:

  • Not having such a diagnosis and/or not being related to such individual.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)
Target follow-up
2 Years
Patient registry
Yes
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. Establish a shared clinical database, biobank of biospecimen samples, and a central repository for the storage of all genetic data in SP-CERN.

    Time frame: 2 years

  2. Synchronize collaborations between institutions and clinical sites through a central research protocol to standardize outcome measures and maximize the quality of research and data to ensure clinical trial readiness by regulatory standards.

    Time frame: 2 years

  3. Test key elements in pilot projects

    Time frame: 2 years

  4. Build comprehensive programs for advancements in diagnosis, provide more opportunities for innovative treatments, and increase access to high-quality healthcare for HSP and PLS patients.

    Time frame: 2 years

Secondary outcomes

  1. Enrollment of 100 individuals with hereditary spastic paraplegia type 4 (SPG4) or hereditary spastic paraplegia type 5A (SPG5A) in the shared clinical database.

    Time frame: 2 years

  2. Biobanking of blood samples from 100 individuals with SPG4 or SPG5A in a shared biobank.

    Time frame: 2 years

07

Study locations

1 of 11 sites recruiting
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2024 (actual). Primary completion is estimated for Jun 2026, 24 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 12, 2024
First posted
Aug 14, 2024
StartActual
Jun 4, 2024
Primary completionEst.
Jun 4, 2026
CompletionEst.
Jun 4, 2027
Last update
Mar 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06553976
Responsible party
Darius Ebrahimi-Fakhari (Principal Investigator, Boston Children's Hospital) — Principal investigator
First posted
Aug 14, 2024
Start date
Jun 4, 2024
Primary completion
Jun 4, 2026 (estimated)
Completion
Jun 4, 2027 (estimated)
Last update
Mar 18, 2026

Study contacts

Darius Ebrahimi-Fakhari, MD, PhD.
Contact
hsp.research@childrens.harvard.edu
617-355-0097
Nicole Battaglia, BS.
Contact
hsp.research@childrens.harvard.edu
617-919-7450

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion